- Home
- SNY vs HASI Comparison
SNY vs HASI Comparison
Compare SNY & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- HASI
- Stock Information
- Founded
- SNY 1994
- HASI 1981
- Country
- SNY France
- HASI United States
- Employees
- SNY N/A
- HASI N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- HASI Real Estate Investment Trusts
- Sector
- SNY Health Care
- HASI Real Estate
- Exchange
- SNY Nasdaq
- HASI Nasdaq
- Market Cap
- SNY 123.6B
- HASI N/A
- IPO Year
- SNY N/A
- HASI 2013
- Fundamental
- Price
- SNY $53.63
- HASI $25.08
- Analyst Decision
- SNY Buy
- HASI Strong Buy
- Analyst Count
- SNY 2
- HASI 11
- Target Price
- SNY $62.50
- HASI $39.36
- AVG Volume (30 Days)
- SNY 3.6M
- HASI 1.4M
- Earning Date
- SNY 04-24-2025
- HASI 05-07-2025
- Dividend Yield
- SNY 3.08%
- HASI 6.79%
- EPS Growth
- SNY 39.56
- HASI 14.02
- EPS
- SNY 5.45
- HASI 1.62
- Revenue
- SNY $48,817,552,946.00
- HASI $140,172,000.00
- Revenue This Year
- SNY $5.35
- HASI $190.42
- Revenue Next Year
- SNY $6.69
- HASI $11.14
- P/E Ratio
- SNY $9.60
- HASI $15.30
- Revenue Growth
- SNY N/A
- HASI 2.29
- 52 Week Low
- SNY $45.80
- HASI $21.98
- 52 Week High
- SNY $60.12
- HASI $36.56
- Technical
- Relative Strength Index (RSI)
- SNY 50.20
- HASI 44.42
- Support Level
- SNY $50.46
- HASI $23.08
- Resistance Level
- SNY $51.64
- HASI $25.18
- Average True Range (ATR)
- SNY 1.60
- HASI 1.37
- MACD
- SNY 0.15
- HASI 0.10
- Stochastic Oscillator
- SNY 65.92
- HASI 55.16
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.